TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of subjects who test positive for markers of Hepatitis B Virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of subjects who test positive for markers of Hepatitis C Virus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of HBV vaccination in subjects with negative HBV serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initiation of therapeutic hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Approaches to Dementia Questionnaire (ADQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Staff Experiences of Working With Demented Residents Scale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuous Glucose Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arteriovenous fistula maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications in hemodialysis patients
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of subsequent episodes of deliberate self harm
Endpoint domain: Adverse events/effects
Primary endpoint: Time elapsed to future episodes of deliberate self harm
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Numeric Rating Score (NRS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of coronary artery abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint of patient prosthesis mismatch and >= moderate paravalvular regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in oxidative damage as indicated by serum 8-hydroxydeoxyguanosine (8-oh-dG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in time to walk 400 m
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical well-being scores on the Functional Assessment of Cancer Therapy-Lung (FACT-L)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in functional well-being scores on the FACT-L
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diagnostic accuracy of chest ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of EONS
Endpoint domain: Adverse events/effects
Primary endpoint: Change in computed tomography (CT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: opioid consumption postop
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Serum HBV DNA <20 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: plasma concentrations of INS37217
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of 18F-FDG PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) for S-Warfarin, Caffeine, Midazolam and Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) for Omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical Success of Guidewire Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: pancreatic fistula rate
Endpoint domain: Adverse events/effects
Primary endpoint: Comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End Tidal Carbondioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Knowledge related to HCV/HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk Behaviors related to HCV/HIV
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Total Body Water differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Eligibility for gene therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful conversion to an organized heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in plasma heme oxygenase 1 (HO-1) protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Monocyte HO-1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct Healthcare Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healthcare Resource Utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Hemoglobin A1c (HbA1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gross Total Resection rate
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with complete virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective Appeal Rating Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: emergent adverse postoperative events
Endpoint domain: Adverse events/effects
Primary endpoint: degree of vascular calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Neck pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress (within-person change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: brain activation on worry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC0-t of padsevonil type 1 tablets during part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of padsevonil type 2 tablets during part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of padsevonil type 1 tablets during part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of the procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Locoregional Response Rate (LRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian Phase Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of samples with increased anti-tumor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change of dysphagia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of gastroesophageal reflux symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stool Consistency Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change from baseline in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Symptomatic or asymptomatic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in volume of foci of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of frequency and intensity of intrusions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maternal weight before delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maternal weight in the early pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of bronchiolitis obliterans syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for change of immunosuppressive medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IGF1 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Grade 3/4 Febrile Neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Bronchoconstriction measured as fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Monocytes counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophils counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Macrophages count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in IBS Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Skin disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression Free Survival (PFS) at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Cmax - Maximum Systemic Concentration of Brimonidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC - Area Under the Curve of Brimonidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time to Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of %Change in TOI to Predict Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - Maximum Plasma Concentration of Levodopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax - Time of Occurrence of Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - Area Under the Concentration-time Curve From Time Zero up to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conjunctival Hyperaemia in the Worse Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Biochemical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Score at Clinician administered PTSD scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Brachial Artery Flow Mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of adverse events related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Medication usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment's duration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in median arterial pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of intravenous fluids transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days in the intensive care unit with systemic inflammatory response syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of selective stimulation and recording from A-delta nerve fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NeuroFit score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Speed During Timed 25-foot Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants Achieving an Increase in Hb of at Least 2 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of correct classified A/V beats
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of linear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain during active mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to Last (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life period (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinued From Study Treatment Due to AEs During the Treatment Period and First 14 Follow-up Days
Endpoint domain: Adverse events/effects
Primary endpoint: Lobene Stain Index Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of contrast-induced nephropathy (CIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Patients With Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FVC Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 percent Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body Constitution Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with psychotic relapse(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of new COVID-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Number of symptom free days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bronchodilator use per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Subjects With at Least One Severe Systemic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Turnover of phenylalanine and tyrosine in skeletal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein signaling cascade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Serum Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of patients with adverse effects during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with adverse pregnancy outcome
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with adverse fetal outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of Celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from intubation to ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in pulmonary diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Time in Range Glucose Levels 63-140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CR Rate in First-line BPDCN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of 3D printed transfer tray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of virulence factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of Canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of probenecid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of participants affected with ocular toxoplasmosis
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in mental state
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of adverse events for the different combinations
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor biomarker identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in hepatic fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evaluation of knee compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: allocations of monetary units
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of recanalized cerebral veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of wound bed preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunity cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Factor Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Maternal Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum levels of plasma estrone (E1), estradiol, E1-conjugates, and E1-sulfates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain With Physical Therapy on Post-operative Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: CGM usefulness score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of signs of Turner syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of implementing decision-making aid
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-reported use of hearing conservation strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to anti-TNF therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Maintained MBL Volume of <80 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of synthetic cannabinoids abusers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient ischemic attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemorrhagic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heavy bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: visualization of abdominal tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cochin Hand Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subjective Ocular Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Ocular Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Ocular Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life time (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the peak drug concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance of PER977 and metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes